Pulse Methylprednisolone Versus Dexamethasone in COVID-19: A Multicenter Cohort Study.

ABSTRACT: Although pulse (high-dose) methylprednisolone therapy can hypothetically control immune system flare-ups effectively, the clinical benefit of pulse methylprednisolone compared with dexamethasone in COVID-19 remains inconclusive.

Objectives

To compare pulse methylprednisolone to dexamethasone as a COVID-19 treatment.

Design setting and participants

Using a Japanese multicenter database, we identified adult patients admitted for COVID-19 and discharged between January 2020 and December 2021 treated with pulse methylprednisolone (250, 500, or 1,000 mg/d) or IV dexamethasone (≥ 6 mg/d) at admission day 0 or 1.

Main outcomes and measures

The primary outcome was in-hospital mortality. Secondary outcomes were 30-day mortality, new ICU admission, insulin initiation, fungal inf

SUBMITTER: Watanabe A 

PROVIDER: S-EPMC10047604 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature